Louisiana to allow ODs to perform certain surgeries

Article

The Lousisiana Legislature passed a bill last week that makes the state the third in the nation to allow optometrists to perform certain surgeries. The bill has gone on to Governor Bobby Jindal for his signature.

Baton Rouge, LA-The Lousisiana Legislature recently passed a bill that makes the state the third in the nation to allow optometrists to perform certain surgeries. The bill has gone on to Governor Bobby Jindal for his signature.

The bill does not provide a list of approved procedures, but rather lists procedures that are still off-limits to ODs, including:

• LASIK

• PRK

• Administration of general anesthesia

• Penetrating keratoplasty, corneal transplant, or lamellar keratoplasty

• Laser or nonlaser injection into the vitreous chamber of the eye to treat any macular or retinal disease

The bill also prohibits a number of nonlaser surgical procedures. (The rest of the list can be found under Section D of the bill)

Optometrists will be able to perform YAG laser capsulotomy, iridotomies, and selective laser trabeculoplasty, among other common procedures. James Sandefur, OD, excutive director of the Optometry Association of Louisiana, told Optometry Times the state’s ODs have been working to pass this bill for three years.

According to Dr. Sandefur, fewer than half of the parishes in LA have ophthalmologists, but nearly all parishes have an optometrist’s office. The new law will allow patients to have easier access to eye care, Dr. Sandefur says, especially for patients in rural areas.

“This will give patients a choice. Ophthalmologists have had a monopoly on these procedures. And this won’t prevent them from going to an ophthalmologist, but it gives them a choice,” says Dr. Sandefur.

Louisiana ODs will have to undergo further education and training established by the Louisiana State Board of Optometry Examiners in order to perform expanded therapeutic procedures.

“This will allow our young doctors to practice in the manner that they’ve been trained in school and for our older doctors to practice in modern, up-to-date manner,” says Dr. Sandefur.

The bill also allows optometrists to prescribe Schedule III drugs. 

Next: Popular diabetes drug linked to reduced glaucoma risk

Many Americans unaware of increased risk to UV exposure for certain drugs, light-colored eyes

Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.